Positive Interim Phase 2 Data Reported For VEGF Trap-Eye In Age-Related Macular Degeneration

Medical News Today

Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. today announced positive preliminary data from a pre-planned interim analysis of their Phase 2 randomized study of their VEGF Trap-Eye in patients with the neovascular form of age-related macular degeneration (wet AMD).
  • <<
  • >>

Comments